Tags

Type your tag names separated by a space and hit enter

Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Adv Chronic Kidney Dis. 2020 09; 27(5):434-441.AC

Abstract

Coronavirus disease 2019, the disease caused by the severe acute respiratory syndrome coronavirus 2 virus, was first identified in the Hubei Province of China in late 2019. Currently, the only role for therapy is treatment of the disease, as opposed to postexposure prophylaxis, however multiple clinical trials are currently ongoing for both treatment and prophylaxis. Treating coronavirus disease 2019 relies on two components; the first is inhibition of the viral entrance and replication within the body and the second is inhibition of an exacerbated immune response which can be seen in patients with severe disease. Many drugs have shown in vitro antiviral activity; however, clinical trials have not been as promising. This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD. While clinical trials are ongoing, most are in patients with normal kidney function. During a pandemic, when patients with CKD are at higher risk of both infection and death, it is imperative to include patients these patients in the clinical trials.

Authors+Show Affiliations

Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH. Electronic address: amit.govil@uc.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33308510

Citation

Miller-Handley, Hilary, et al. "Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function." Advances in Chronic Kidney Disease, vol. 27, no. 5, 2020, pp. 434-441.
Miller-Handley H, Luckett K, Govil A. Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. Adv Chronic Kidney Dis. 2020;27(5):434-441.
Miller-Handley, H., Luckett, K., & Govil, A. (2020). Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. Advances in Chronic Kidney Disease, 27(5), 434-441. https://doi.org/10.1053/j.ackd.2020.09.001
Miller-Handley H, Luckett K, Govil A. Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. Adv Chronic Kidney Dis. 2020;27(5):434-441. PubMed PMID: 33308510.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. AU - Miller-Handley,Hilary, AU - Luckett,Keith, AU - Govil,Amit, Y1 - 2020/09/17/ PY - 2020/07/07/received PY - 2020/09/08/revised PY - 2020/09/15/accepted PY - 2020/12/14/entrez PY - 2020/12/15/pubmed PY - 2021/1/5/medline KW - COVID-19 KW - Coronavirus KW - Kidney dysfunction KW - SARS-CoV-2 KW - Treatment SP - 434 EP - 441 JF - Advances in chronic kidney disease JO - Adv Chronic Kidney Dis VL - 27 IS - 5 N2 - Coronavirus disease 2019, the disease caused by the severe acute respiratory syndrome coronavirus 2 virus, was first identified in the Hubei Province of China in late 2019. Currently, the only role for therapy is treatment of the disease, as opposed to postexposure prophylaxis, however multiple clinical trials are currently ongoing for both treatment and prophylaxis. Treating coronavirus disease 2019 relies on two components; the first is inhibition of the viral entrance and replication within the body and the second is inhibition of an exacerbated immune response which can be seen in patients with severe disease. Many drugs have shown in vitro antiviral activity; however, clinical trials have not been as promising. This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD. While clinical trials are ongoing, most are in patients with normal kidney function. During a pandemic, when patients with CKD are at higher risk of both infection and death, it is imperative to include patients these patients in the clinical trials. SN - 1548-5609 UR - https://www.unboundmedicine.com/medline/citation/33308510/Treatment_Options_for_Coronavirus_Disease_2019_in_Patients_With_Reduced_or_Absent_Kidney_Function_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1548-5595(20)30133-6 DB - PRIME DP - Unbound Medicine ER -